Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
2.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism.

Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M.

Cancer Res. 2017 Mar 1;77(5):1188-1199. doi: 10.1158/0008-5472.CAN-16-0754. Epub 2016 Dec 28.

3.

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.

Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Böttcher S, Bargou RC, Binder M.

Blood. 2017 Jan 5;129(1):100-104. doi: 10.1182/blood-2016-05-718395. Epub 2016 Oct 26.

4.

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.

Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K.

Oncotarget. 2016 Jul 19;7(29):45122-45133. doi: 10.18632/oncotarget.9161.

5.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.

Braig F, Voigtlaender M, Schieferdecker A, Busch CJ, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M.

Oncotarget. 2016 Jul 12;7(28):42988-42995. doi: 10.18632/oncotarget.8943.

6.

A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma.

Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M.

Blood. 2016 Jun 23;127(25):3202-14. doi: 10.1182/blood-2015-10-676536. Epub 2016 Mar 31.

7.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.

Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M.

Oncotarget. 2015 May 20;6(14):12035-47.

8.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.

Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M.

Oncotarget. 2014 Aug 30;5(16):6647-53.

9.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.

Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M.

Neoplasia. 2012 Nov;14(11):1023-31.

10.

Influence of professional cleaning and drying of occlusal surfaces on laser fluorescence in vivo.

Lussi A, Longbottom C, Gygax M, Braig F.

Caries Res. 2005 Jul-Aug;39(4):284-6.

PMID:
15942188
11.

Collagen implant: an early assessment.

Ellis DA, Braig F, Robertson C.

J Otolaryngol. 1984 Aug;13(4):267-70.

PMID:
6471164
12.

Tracheotomy in longterm management of sleep apnea.

Dayal VS, Braig F.

J Otolaryngol. 1981 Aug;10(4):273-7.

PMID:
6795363

Supplemental Content

Support Center